Salvatore Pisconti

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

Nicola Normanno, Anna Maria Rachiglio, Matilde Lambiase et al. · Annals of Oncology · 2015 · 145 citations · Full text

Capri Goim Trial, Medicine, Pathology +8

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial

Nicola Normanno, Riziero Esposito Abate, Matilde Lambiase et al. · Annals of Oncology · 2017 · 117 citations

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

Fortunato Ciardiello, Nicola Normanno, Evaristo Maiello et al. · Annals of Oncology · 2014 · 116 citations · Full text

Translational Medicine, Oncology, Gene Mutation Status +11

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Fortunato Ciardiello, Nicola Normanno, Erika Martinelli et al. · Annals of Oncology · 2016 · 97 citations

Gastrointestinal Oncology, Cetuximab Continuation, Medicine +8

Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial

Domenico Galetta, Saverio Cinieri, Salvatore Pisconti et al. · Clinical Lung Cancer · 2014 · 77 citations · Full text

Maintenance Bevacizumab, Medicine, Metronomic Therapy +7